Jüttner F M, Smolle J, Popper H, Pinter H H, Friehs G
Onkologie. 1986 Oct;9(5):250-3. doi: 10.1159/000216021.
Bleomycin (BLM) was given perioperatively and 3 and 6 months postoperatively in a dosage of 150 mg per course (total: 450 mg) to 37 patients with surgically resectable squamous-cell lung cancer. 37 randomized control patients with resectable squamous-cell lung cancer were compared to the chemotherapy-group. 5-year overall survival of the BLM group was 46.3%, that of the controls 40.5% (Mantel-Haenszel test; p greater than 0.05). BLM-treated stage I showed a 5-year survival of 47.9% (controls: 55%), BLM stage II 50% (controls: 33.3%), BLM stage III 40% (controls: 21.4%). The difference is not statistically significant. No severe adverse effects of therapy on either wound healing, or perioperative mortality of lung function were observed.
对37例可手术切除的鳞状细胞肺癌患者在围手术期、术后3个月和6个月给予博来霉素（BLM），每疗程剂量为150mg（总计450mg）。将37例随机对照的可切除鳞状细胞肺癌患者与化疗组进行比较。BLM组的5年总生存率为46.3%，对照组为40.5%（Mantel-Haenszel检验；p大于0.05）。接受BLM治疗的I期患者5年生存率为47.9%（对照组：55%），BLM组II期为50%（对照组：33.3%），BLM组III期为40%（对照组：21.4%）。差异无统计学意义。未观察到治疗对伤口愈合或肺功能围手术期死亡率有严重不良反应。
